gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Glucagon receptor

glucagon receptor, GCGR
The protein encoded by this gene is a glucagon receptor that is important in controlling blood glucose levels. Defects in this gene are a cause of non-insulin-dependent diabetes mellitus (NIDDM).[provided by RefSeq, Jan 2010] (from NCBI)
Top mentioned proteins: Glucagon, Insulin, E4, ACID, CAN
Papers on glucagon receptor
Evidence for time dependent variation of glucagon secretion in mice.
Ahrén et al., Lund, Sweden. In Peptides, Feb 2016
We therefore examined glucagon secretion after meal ingestion (meal tolerance test) and during hypoglycemia (hyperinsulinemic hypoglycemia clamp at 2.5mmol/l glucose) and in vitro from isolated islets at ZT3 versus ZT15 in normal C57BL/6J mice and, furthermore, glucose levels and the insulin response to meal ingestion were also examined at these time points in glucagon receptor knockout mice (GCGR-/-) and their wildtype (wt) littermates.
Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice.
Ahren et al., Lund, Sweden. In J Endocrinol, Jan 2016
UNASSIGNED: Stimulation of insulin secretion by short-term glucagon receptor (GCGR) activation is well characterized, however, the effect of long-term GCGR activation on beta-cell function is not known, but of interest, since hyperglucagonemia occurs early during development of type 2 diabetes.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes.
Deeg et al., Indianapolis, United States. In Diabetes Care, Jan 2016
LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose, was evaluated for efficacy and safety in patients with type 2 diabetes.
An AlphaScreen Assay for the Discovery of Synthetic Chemical Inhibitors of Glucagon Production.
Roth et al., Dallas, United States. In J Biomol Screen, Jan 2016
Recent efforts to control glucagon in diabetes have focused on antagonizing the glucagon receptor, which is effective in lowering blood glucose levels but leads to hyperglucogonemia in rodents.
[The trend of new drug development for the treatment of diabetes mellitus].
Kaku, In Nihon Rinsho, Dec 2015
The hypoglycemic drugs such as glucagon receptor antagonists, glucokinase activators, and GPR agonists and oral medication of GLP-1 receptor agonist are under phase 2 trial in Japan.
Recent progress in the development of small-molecule glucagon receptor antagonists.
Lee et al., Cambridge, United States. In Bioorg Med Chem Lett, Nov 2015
The endocrine hormone glucagon stimulates hepatic glucose output via its action at the glucagon receptor (GCGr) in the liver.
Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.
Wang et al., Shanghai, China. In Acta Pharmacol Sin, Sep 2015
Following our discovery of non-peptidic agonists for glucagon-like peptide-1 receptor (GLP-1R) that have therapeutic effects, we initiated collaborative efforts in structural biology and recently solved the three-dimensional (3D) structure of the human glucagon receptor (GCGR) 7-transmembrane domain, providing in-depth information about the underlying signaling mechanisms.
Inhibiting or antagonizing glucagon: making progress in diabetes care.
Scheen et al., Liège, Belgium. In Diabetes Obes Metab, Aug 2015
Recent studies have shown that knockout of the glucagon receptor or administration of a monoclonal specific glucagon receptor antibody make insulin-deficient type 1 diabetic rodents thrive without insulin.
The galectin lattice at a glance.
Dennis et al., Toronto, Canada. In J Cell Sci, Aug 2015
The galectin lattice also regulates the selection, activation and arrest of T cells, receptor kinase signaling and the functionality of membrane receptors, including the glucagon receptor, glucose and amino acid transporters, cadherins and integrins.
Recent Advances in Synthetic Chemistry of Diabetic Research.
Morel et al., Rio de Janeiro, Brazil. In Mini Rev Med Chem, 2014
Extensive research has been carried out using rational drug design to identify and optimize new leads for molecular targets of T2DM, which include Heterocyclic compounds, metal complexes, H3 receptor antagonists, glucagon receptor antagonists and human incretin-degrading enzyme dipeptidyl peptidase IV inhibitors.
Structure of the human glucagon class B G-protein-coupled receptor.
Stevens et al., Los Angeles, United States. In Nature, 2013
Binding of the glucagon peptide to the glucagon receptor (GCGR) triggers the release of glucose from the liver during fasting; thus GCGR plays an important role in glucose homeostasis.
Hypothalamic glucagon signaling inhibits hepatic glucose production.
Lam et al., Toronto, Canada. In Nat Med, 2013
Inhibition of glucagon receptor-PKA signaling in the MBH and hepatic vagotomy each negated the effect of MBH glucagon in rats, whereas the central effect of glucagon was diminished in glucagon receptor knockout mice.
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.
Guzman-Perez et al., United States. In Bioorg Med Chem Lett, 2012
analysis of glucagon receptor antagonists with reduced molecular weight and lipophilicity
Modulation of β-catenin signaling by glucagon receptor activation.
Xu et al., Grand Rapids, United States. In Plos One, 2011
in addition to activation of the classic cAMP/protein kinase A (PKA) pathway, activation of GCGR also induced beta-catenin stabilization and activated beta-catenin-mediated transcription
A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling.
Zhou et al., Los Angeles, United States. In Endocrinol Nutr, 2011
The P86S mutant GCGR shows abnormal receptor internalization & calcium mobilization, & causes apoptosis. It cases Mahvash disease (hyperglucagonemia, hypoglycemia, pancreatic neuroendocrine tumors).
Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain.
Waelbroeck et al., Brussels, Belgium. In J Biol Chem, 2010
substituted cysteine accessibility method and 3D-molecular modeling to study the N-terminal domain; results showed that Asp(63), Arg(116), and Lys(98) are essential for the receptor structure and/or ligand binding
Glucagon receptor mediates calcium signaling by coupling to G alpha q/11 and G alpha i/o in HEK293 cells.
Xie et al., Shanghai, China. In J Recept Signal Transduct Res, 2009
The [Ca2+] response is induced by glucagon mainly via the coupling of GCGR to the Galphaq/11 and Galphai/o proteins.
The glucagon receptor is required for the adaptive metabolic response to fasting.
Drucker et al., Toronto, Canada. In Cell Metab, 2008
Glucagon receptor (Gcgr) signaling maintains hepatic glucose production during the fasting state; however, the importance of the Gcgr for lipid metabolism is unclear.
The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.
Gerich et al., Princeton, United States. In Endocr Rev, 2007
Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, alpha-cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors.
International Union of Pharmacology. XXXV. The glucagon receptor family.
Drucker et al., Evanston, United States. In Pharmacol Rev, 2003
Peptide hormones within the secretin-glucagon family are expressed in endocrine cells of the pancreas and gastrointestinal epithelium and in specialized neurons in the brain, and subserve multiple biological functions, including regulation of growth, nutrient intake, and transit within the gut, and digestion, energy absorption, and energy assimilation.
share on facebooktweetadd +1mail to friends